ASCO 2026 Conference Intelligence

My Top 10 Breast Cancer Abstracts at #ASCO26 👇 https://t.co/BCHikR7VLK

With @myESMO Breast Cancer 2026 around the corner, we asked leading AI models to identify the most anticipated trials in breast cancer, here’s their combined ranking. There's strong consensus around trials like DESTINY-Breast11, SATEEN, and TRAIN-4—highlighting continued https://t.co/chZm3F3kzf

Super excited for #ASCO26 🙌 Completely agree—one of the best parts of @ASCO is seeing friends and colleagues from around the globe. Can’t wait to catch up and of course see the superstar @OncBrothers 🤩 https://t.co/lJ4T7P9fm2

Follow the #ASCO26 Pre-conference updates from global KOLs! Updated Daily!!! https://t.co/Jk4FnjQas2 Follow their most anticipated Trials👉 GI Cancer: @GIMedOnc Multiple Myeloma: @HadidiSamer GU Cancer: @DrChoueiri @DrKarineTawagi Breast Cancer: @dr_yakupergun @SuyogCancer

We are gearing up for our coverage of the 2026 ASCO Annual Meeting, and we want to hear your thoughts! We'll be posting polls below asking for the breast and lung cancer insights you're most excited to see at the meeting. Make sure to vote, and stay tuned for the results! @ASCO

#ASCO26 is coming up! With abstracts released I put together a top 10 (ok, top 12) GI abstracts I'm excited for. Some things might fall off (or be added) pending full abstract text, but these are what I'm watching for and might be practice changing or scientifically https://t.co/RpFKvdnZlJ

As #ASCO26 is approaching, here are my top 10 GU abstracts to be presented (based on the titles). 1-Abstract LBA1: PROTEUS In high-risk localized prostate cancer, intensifying perioperative therapy may improve long-term outcomes, #DrMaryEllenTaplin from @DanaFarber_GU will https://t.co/5NjVPXJ50L

#ASCO26 @ASCO abstracts are out, looking for a great meeting #mmsm @utswcancer Here are my top 5 plasma cell disorders to watch for 🧵 1⃣MajesTEC-9: RCT of teclistamab monotherapy vs PVd/Kd in RRMM: press release with PFS and OS benefit. Will allow for earlier use of single https://t.co/BiaHZKDmbs

Impact of 1L amivantamab + lazertinib vs osimertinib on acquired resistance in EGFR mutant NSCLC @JTOonline. Ami/laz reduces MET amp (3.4% vs 13.1%) and acquired EGFR resistance mts (1.4% vs 7.6%). 2L PFS longer in ami/laz arm vs osi (8.4m vs 5.3m). https://t.co/UYIfOrJEmZ

This week's Biotech Scorecard: An #ASCO26 mystery: What does Akeso’s primo plenary spot say about its ivonescimab lung cancer survival data? $SMMT If the news was good, we'd have heard by now, right? Or, is Akeso just being ultra conservative? https://t.co/onSduihfrl

🆙 #ASCO26 #LCSM Oral Abstract Session 🔥CROWN: Lorlatinib vs Crizotinib as First-Line Treatment for Advanced ALK+ NSCLC: 7-Year Update 🎙️ @TonyMok9 🔢8502 ☑️NCT03052608 🔗 https://t.co/GgYuAT6KsN @OncoAlert @Larvol @ASCO https://t.co/CVByWraVH8 https://t.co/JcbFKPl6DZ

Patients with KRAS G12D+ #lungcancer are also still desperately waiting for an effective targeted therapy. How can we accelerate tumor-agnostic approvals, especially when current treatments fall short? @KRASKickers @VivekSubbiah #daraxonrasib @RevMedicines https://t.co/BMZPqUA81p

🧬 Amivantamab + lazertinib doesn’t just improve outcomes — it reshapes resistance. 🔻 MET amplification 🔻 EGFR resistance mutations 🔺 “Unknown” resistance ⏱️ ➡️ Longer 2L PFS 💥 Not just delaying progression… 👉 It may be changing tumor evolution @OncoAlert @OncoReporte https://t.co/nz40cE6g3b

First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer https://t.co/hek4yk2UUN https://t.co/3xRfrxhAzI

My Top 10 Breast Cancer Abstracts at #ASCO26 👇 https://t.co/BCHikR7VLK

What's New data in breast cancer at ASCO 2026 ? Check this out 🙂👇 @ASCO #ASCO26 https://t.co/8AghUs7Bsr

JUST IN: @FDA approves Vepdegestrant (heterobifunctional protein degrader) for ER+/HER2– Advanced Breast Cancer with an ESR1 Mutation. Trial led by @ErikaHamilton9 and presented @ASCO #ASCO25 Link: https://t.co/23AqFJ9hpL https://t.co/rgU6Wrbd4Z

Hi friends, it's #BreastCancer Tuesday! Here are Top Posts of the Week 🧵 1/ @SuyogCancer on top abstracts at #ASCO26: https://t.co/r6BAjgcPvk ── 3/ @to_be_elizabeth on 10-year results of SiFEBI phase 2 trial: https://t.co/Yh34CVBQvf ── 2/ @DrBarbiOnc on zanidatamab in early HER2 IHC 3+, ERBB2-amplified BC at #AACR26: https://t.co/PfZ5Y5yaMm ── 4/ @breastfriendspd on a special Miami edition with @JAMouabbi @PTarantinoMD and @curijoey: https://t.co/BPBnir90l3 ── What are https://t.co/RBIzLjYaoW Top Posts of the Week? 👉The most influential posts from last week by reposts, replies and likes. ── 5/ @LabPolyak on novel targets during evolution to resistance to HER2-targeted therapies via @DFCI_BreastOnc: https://t.co/PMYnLDxZ0O ── Love #MedTwitter but not the noise? Get practice changing updates from social media. Subscribe to our weekly newsletter and join your colleagues. Sign up free! https://t.co/KsxGWQxmCS

Great News! Arvinas received FDA approval for VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after prior endocrine therapy. $ARVN $PFE #ASCO26 https://t.co/g9n5cceCM6

Follow the #ASCO26 Pre-conference updates from global KOLs! Updated Daily!!! https://t.co/Jk4FnjQas2 Follow their most anticipated Trials👉 GI Cancer: @GIMedOnc Multiple Myeloma: @HadidiSamer GU Cancer: @DrChoueiri @DrKarineTawagi Breast Cancer: @dr_yakupergun @SuyogCancer

To clarify, Mr. Sasse has one cancer - #PancreaticCancer - that has metastasized to multiple sites. However at the molecular level these individual tumors look distinct enough that they might as well be separate. Nonetheless they all share the Daraxonrasib target- KRAS mutation. https://t.co/dbKPcYAIlH

✨ ICI in localized CRC (#ASCO26 ed book) 🔹 dMMR/MSI-H → unprecedented responses 🔹 Rectal MSI-H → watch & wait as organ-preserving 🔹 ctDNA: promising, not yet practice-changing 🔹 MSS CRC → major unmet need 🚀 Moving toward precision, response-adapted strategies 🔗 https://t.co/I8QOOhqg6l

Therapeutic options in CRC are expanding; treatment selection is moving beyond the simple presence or absence of RAS mutations toward a more refined strategy targeting tumor signaling dependency and resistance biology. @ASCO Educational Book👇 https://t.co/jqc3srUjtx https://t.co/Kg69iUWhuJ

More details on daraxonrasib EAP Has to be initiated by prescribing doc via email to RevMed, reply guaranteed within 2d https://t.co/XBtPnZ7cd3

Just in via @nytimes: The @FDA would permit patients with deadly pancreatic cancer to receive early access to daraxonrasib (RAS inhibitor, molecular glue) before approval. https://t.co/wCZ1X7iyRq @ginakolata @RebeccaDRobbins

Breaking the 40-year silence in Pancreatic Cancer! The #FDA just granted Expanded Access for Daraxonrasib, a first-in-class multi-selective RAS(ON) inhibitor. #PancreaticCancer #Oncology #PrecisionMedicine #MedTwitter #Daraxonrasib https://t.co/SfW0kUrLKU

As #ASCO26 is approaching, here are my top 10 GU abstracts to be presented (based on the titles). 1-Abstract LBA1: PROTEUS In high-risk localized prostate cancer, intensifying perioperative therapy may improve long-term outcomes, #DrMaryEllenTaplin from @DanaFarber_GU will https://t.co/5NjVPXJ50L

GU schedule by day 📆 for #ASCO26 & (among others) looking forward to 💫 1) Bladder CA: -Data on novel nectin-4 ADCs: #NEXUS01, #EXCEED + #DURAVELO2, Bulumtatug, SHR-A2102 -Updates for: #EV302, #KN905 QoL -RAD-IO TMT w/ durva  -GemFLP in bladder adenoCA https://t.co/Y199O2urSC ── 2) Kidney CA: -NonCC-RCC: cadonilimab (PD1/CTLA4 bispecific),final ph2 cabo/nivo -Updates: #KN564 ctDNA -Panitumumab-based EGFR block in SAMRCB1-deficient RMC ── 3) Prostate CA: -#PROTEUS: perioperative apalutamide (plenary!) -mCSPC: identifying docetaxel benefit analyses from CHAARTED + ENZAMET, & ADT interruption #ADREAM, PARPi #TALAPRO3, #PSMAddition, ZZ-First -mCRPC: ADC to PSMA/STEAP1, #PLUDO doce vs Lu-617, AVPC chemo-IO ── 4) Testicular CA: -SWOG S1823 microRNA in predicting active GCT -Expert session on Optimizing Tx for Pts with Poor-Risk Testicular Cancer

@asco #asco26 is four weeks away. Looking forward to seeing everyone in Chicago. Eagerly awaited: Plenary Session trials PROTEUS - Perioperative apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized / locally advanced prostate cancer SARC041 - https://t.co/A33pOdQV7K

💥 @US_FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC based on data from the phase 3 KEYNOTE-B15/EV-304 trial. Full details 📈: https://t.co/JENvanUfyo #blcsm #oncology

🔬 Belzutifan + lenvatinib may reshape post–IO care in advanced RCC. In phase III LITESPARK-011, the combo improved PFS (14.8 vs 10.7 months), ORR vs cabozantinib. ➡️ Trend toward OS benefit. 🗣️ Presented by @motzermd of @MSK_DeptOfMed at #GU26 https://t.co/PRDKdDovbo https://t.co/xtgExtwPc1

Tian Zhang (@TiansterZhang) highlights key #GU26 data in #KidneyCancer, including LITESPARK-011 & LITESPARK-022 📊 See how these trials can impact clinical practice here: https://t.co/UoCwNAUcpG #gusm #oncology

$IDYA IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma More Info: https://t.co/GHGrqamvxP

$IDYA IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

🔬 PFS improvements were shown for frontline darovasertib plus crizotinib in metastatic uveal melanoma, helping to address a high area of unmet need. Read more here 📈: https://t.co/oPzhATNQRe #melsm #oncology

@ASCO Plenaries: ➡️ seeing #sarcoma + #pancreas take main stage for practice changing trials = amazing! ➡️ Two #lungcancer studies featuring areas of need: #squamous + #earlystage ➡️ Look forward to learning with colleagues from around the 🌎! #ASCO26 @OncoAlert https://t.co/bUDQTVDv05

🚨 Happening at #ASCO2026 OncoDaily Grand Rounds: Sarcoma Edition Co-chaired by Dr. Sandra D'Angelo (@sandrapdangelo) & Dr. Herbert Loong (@herbloong) Featuring Dr. Javier Martin-Broto (@BrotoJavier) & Dr. Robin Jones 📅May 29, 2026 | 🕒 3:30 – 5:30 pm 📍Hilton Chicago https://t.co/pLlo1S0Dk9

#CCR8 Another of the (presumably failed) phase I trials will be at #ASCO26. Remember, a notation says that it was not terminated due to tox. "A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti–PD-1) in patients with solid tumors." https://t.co/KwHTY1v9go